Department of Urology, Ludwig-Maximilians-University of Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Department of Radiology, Ludwig-Maximilians-University of Munich, Munich, Germany.
World J Urol. 2024 Jul 22;42(1):432. doi: 10.1007/s00345-024-05108-9.
While the impact of treatment with 5-alpha Reductase Inhibitors (5-ARI) on the risk of cancer-related mortality in men with prostate cancer (PC) has been extensively studied, little is known about the impact of preoperative 5-ARI use on patient-reported outcomes (PROs) following radical prostatectomy (RP).
Within our prospectively maintained institutional database of 5899 patients treated with RP for PC (2008- 2021), 99 patients with preoperative 5-ARI therapy were identified. A 1:4 propensity-score matched analysis of 442 men (n = 90 5-ARI, n = 352 no 5-ARI) was conducted. Primary endpoint was continence recovery using daily pad usage and ICIQ-SF. Health-related quality of life (HRQOL) was assessed using the validated EORTC QLQ-C30 and PR25 questionnaires. Multivariable Cox-regression-models tested the effect of preoperative 5-ARI treatment on continence-recovery (p < 0.05).
Patients were followed up perioperatively, followed by annual assessments up to 60mo postoperatively. Preoperative mean ICIQ-SF score (2.2 vs. 0.9) was significantly higher in the 5-ARI cohort (p = 0.006). 24mo postoperatively, 68.6% (no 5-ARI) vs. 55.7% (5-ARI) had full continence recovery (p = 0.002). Multivariable Cox regression analysis, revealed preoperative 5-ARI treatment as an independent predictor for impaired continence recovery (HR 0.50, 95% CI 0.27-0.94, p = 0.03) In line, general HRQOL was significantly higher for patients without 5-ARI only up to 24mo postoperatively (70.6 vs. 61.2, p = 0.045). There was no significant impact of preoperative 5-ARI treatment on erectile function, biochemical recurrence-free survival and metastasis-free survival.
Pre-RP 5-ARI treatment was associated with impaired continence outcomes starting 24mo postoperatively, suggesting that preoperative 5-ARI treatment can impair the long-term urinary function recovery following RP.
虽然 5-α 还原酶抑制剂(5-ARI)治疗对前列腺癌(PC)患者癌症相关死亡率的影响已得到广泛研究,但对于术前使用 5-ARI 对根治性前列腺切除术(RP)后患者报告结局(PRO)的影响知之甚少。
在我们前瞻性维护的 5899 例接受 RP 治疗的 PC 患者的机构数据库中,确定了 99 例术前使用 5-ARI 治疗的患者。对 442 名患者(n=90 例 5-ARI,n=352 例无 5-ARI)进行了 1:4 的倾向评分匹配分析。主要终点是使用日常垫使用和 ICIQ-SF 评估的控尿恢复。使用经过验证的 EORTC QLQ-C30 和 PR25 问卷评估健康相关生活质量(HRQOL)。多变量 Cox 回归模型测试了术前 5-ARI 治疗对控尿恢复的影响(p<0.05)。
患者在围手术期接受随访,然后在术后 60 个月进行年度评估。5-ARI 组的术前平均 ICIQ-SF 评分(2.2 对 0.9)显著更高(p=0.006)。术后 24 个月,68.6%(无 5-ARI)与 55.7%(5-ARI)有完全控尿恢复(p=0.002)。多变量 Cox 回归分析显示,术前 5-ARI 治疗是控尿恢复受损的独立预测因素(HR 0.50,95%CI 0.27-0.94,p=0.03)。同样,只有在术后 24 个月内,无 5-ARI 的患者的一般 HRQOL 显著更高(70.6 对 61.2,p=0.045)。术前 5-ARI 治疗对勃起功能、生化无复发生存和无转移生存没有显著影响。
RP 前 5-ARI 治疗与术后 24 个月开始的控尿结果受损相关,表明术前 5-ARI 治疗可能会损害 RP 后长期的尿功能恢复。